(Q38908823)

7 September 2017

1 reference

title

Old and new acetylcholinesterase inhibitors for Alzheimer's disease (English)

1 reference

7 September 2017

0 references

Daniela Galimberti

1

0 references

Elio Scarpini

object named as

Elio Scarpini

series ordinal

2

0 references

language of work or name

English

0 references

publication date

26 July 2016

1 reference

Expert Opinion on Investigational Drugs

7 September 2017

1 reference

7 September 2017

25

1 reference

7 September 2017

10

1 reference

7 September 2017

1181-1187

1 reference

A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia

7 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Phenserine efficacy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Huperzine A for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Design, synthesis and evaluation of novel 7-aminoalkyl-substituted flavonoid derivatives with improved cholinesterase inhibitory activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ1-42 Aggregation Inhibitors for Alzheimer's Disease Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer's Disease Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Taxodione and Extracts from Salvia austriaca Roots as Human Cholinesterase Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2016.1216972

10.1080/13543784.2016.1216972

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27459153